⌘K
Loading ticker…
As of 2026-08-24, Apyx Medical Corporation Common Stock (APYX) has a 3-month relative strength percentile of 16 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 46. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 8.6%, relative volume 0.98×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
APYX appears in 1 ETF as of Apr 2026: DFAC at 0.00% weight, $2K notional.
Held by 4 ETFs · $6M across latest filings · largest weight 0.02% (IWC).
Top 1 by value, from SEC N-PORT-P filings dated Apr 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| DFACDimensional U.S. Core Equity 2 ETF | 0.00% | $2K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | APYX Jan avg: 4.07% median: 3.00% win: 50% σ: 18.78% n: 4 2022-04-12 → 2026-07-31 | APYX Feb avg: -3.23% median: -2.78% win: 50% σ: 12.57% n: 4 2022-04-12 → 2026-07-31 | APYX Mar avg: -9.82% median: -8.45% win: 25% σ: 19.84% n: 4 2022-04-12 → 2026-07-31 | APYX Apr avg: -8.57% median: -9.76% win: 40% σ: 20.60% n: 5 2022-04-12 → 2026-07-31 | APYX May avg: 46.51% median: 50.00% win: 100% σ: 29.45% n: 5 2022-04-12 → 2026-07-31 | APYX Jun avg: 2.77% median: -3.46% win: 40% σ: 26.73% n: 5 2022-04-12 → 2026-07-31 | APYX Jul avg: 10.05% median: 1.49% win: 60% σ: 30.41% n: 5 2022-04-12 → 2026-07-31 | APYX Aug avg: -13.52% median: -9.42% win: 25% σ: 19.34% n: 4 2022-04-12 → 2026-07-31 (current) | APYX Sep avg: -13.05% median: -14.20% win: 25% σ: 17.04% n: 4 2022-04-12 → 2026-07-31 | APYX Oct avg: 4.72% median: 2.86% win: 50% σ: 29.50% n: 4 2022-04-12 → 2026-07-31 | APYX Nov avg: 2.05% median: 17.70% win: 75% σ: 47.09% n: 4 2022-04-12 → 2026-07-31 | APYX Dec avg: 7.35% median: 4.58% win: 50% σ: 19.63% n: 4 2022-04-12 → 2026-07-31 |